Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open Label, Uncontrolled, Phase IIA Clinical Trial Evaluating the Safety and Efficacy of NOX A12 in Combination With a Background Therapy of Bendamustine and Rituximab (BR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)

NCT01486797 is registered in ClinicalTrials.gov with TME Pharma AG as lead sponsor.

NCT NCT01486797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01486797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open Label, Uncontrolled, Phase IIA Clinical Trial Evaluating the Safety and Efficacy of NOX A12 in Combination With a Background Therapy of Bendamustine and Rituximab (BR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
TME Pharma AG
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2012
Completion date
April 30, 2017
Enrollment
28 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia